Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Cerilliant
QuintilesIMS
Johnson and Johnson
McKinsey
Dow
Fish and Richardson
Queensland Health
Express Scripts
Fuji
Federal Trade Commission

Generated: August 21, 2017

DrugPatentWatch Database Preview

Abbvie Company Profile

« Back to Dashboard

What is the competitive landscape for ABBVIE, and when can generic versions of ABBVIE drugs launch?

ABBVIE has eighty-eight approved drugs.

There are eighty-six US patents protecting ABBVIE drugs.

There are one thousand four hundred and twenty-five patent family members on ABBVIE drugs in sixty-nine countries.

Summary for Applicant: Abbvie

Patents:86
Tradenames:77
Ingredients:64
NDAs:88
Drug Master File Entries: (click here to view)1
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie
KALETRA
lopinavir; ritonavir
TABLET;ORAL021906-001Oct 28, 2005RXYesYes► Subscribe► Subscribe ► Subscribe
Abbvie
TEVETEN HCT
eprosartan mesylate; hydrochlorothiazide
TABLET;ORAL021268-001Nov 1, 2001DISCNNoNo► Subscribe► Subscribe► Subscribe
Abbvie
TEVETEN HCT
eprosartan mesylate; hydrochlorothiazide
TABLET;ORAL021268-002Nov 1, 2001DISCNNoNo► Subscribe► Subscribe► Subscribe
Abbvie
KALETRA
lopinavir; ritonavir
TABLET;ORAL021906-002Nov 9, 2007RXYesNo► Subscribe► SubscribeY► Subscribe
Abbvie Inc
VIEKIRA XR
dasabuvir sodium; ombitasvir; paritaprevir; ritonavir
TABLET, EXTENDED RELEASE;ORAL208624-001Jul 22, 2016RXYesYes► Subscribe► SubscribeYY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Abbvie

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie
DEPAKOTE ER
divalproex sodium
TABLET, EXTENDED RELEASE;ORAL021168-001Aug 4, 2000► Subscribe► Subscribe
Abbvie
NORVIR
ritonavir
SOLUTION;ORAL020659-001Mar 1, 1996► Subscribe► Subscribe
Abbvie
ZEMPLAR
paricalcitol
CAPSULE;ORAL021606-003May 26, 2005► Subscribe► Subscribe
Abbvie
KALETRA
lopinavir; ritonavir
TABLET;ORAL021906-001Oct 28, 2005► Subscribe► Subscribe
Abbvie Endocrine Inc
LUPRON DEPOT
leuprolide acetate
INJECTABLE;INJECTION020517-002May 30, 1997► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for ABBVIE drugs

Drugname Dosage Strength Tradename Submissiondate
lopinavir and ritonavir
Oral Solution80 mg/20 mg per mL
KALETRA
6/19/2014
testosterone
Gel1.62% (1.25 g and 2.5 g packets)
ANDROGEL
6/19/2013
ritonavir
Capsules100 mg
NORVIR
10/31/2012
testosterone
Gel1.62%
ANDROGEL
4/6/2012
ritonavir
Tablets100 mg
NORVIR
12/21/2010
clarithromycin
Extended-release Tablet500 mg
BIAXIN XL
12/6/2010
eprosartan mesylate
Tablets400 mg and 600 mg
TEVETEN
5/10/2010
fenofibrate choline
Delayed-release Capsules45 mg
TRILIPIX
9/2/2009
fenofibrate choline
Delayed-release Capsules135 mg
TRILIPIX
9/1/2009
cisatracurium besylate (multi-dose)
     Injection2 mg/mL, 10 mL vial
NIMBEX
8/12/2009
cisatracurium besylate (preserve free)
Injection2 mg/mL, 5 mL vial and 10 mg/mL, 20 mL vial
NIMBEX
8/4/2009
lopinavir and ritonavir
Tablets100 mg/25 mg
KALETRA
12/23/2008
testosterone
Gel Metered-dose Pump1%
ANDROGEL
12/19/2008
paricalcitol
Injection0.002 mg per mL in 1 mL vial and 0.005 mg per mL in 1 mL and 2 mL vials
ZEMPLAR
11/28/2008
paricalcitol
Capsules1 mcg and 2 mcg
ZEMPLAR
10/14/2008
paricalcitol
Capsules4 mcg
ZEMPLAR
8/25/2008
fenofibrate
Tablets48 mg
TRICOR
7/1/2008
trandolapril and verapamil hydrochloride
Extended-release Tablets1 mg/240 mg
TARKA
2/20/2008
trandolapril and verapamil hydrochloride
Extended-release Tablets2 mg/180 mg and 2 mg/240 mg
TARKA
11/9/2007
fenofibrate
Tablets145 mg
TRICOR
10/19/2007
trandolapril and verapamil hydrochloride
Extended-release Tablets4 mg/ 240 mg
TARKA
7/24/2007
hydrocodone bitartrate and ibuprofen
Tablets2.5 mg/200 mg
VICOPROFEN
2/24/2006
hydrocodone bitartrate and ibuprofen
Tablets5 mg/200 mg
VICOPROFEN
5/27/2005
divalproex sodium
Extended-release Tablets500 mg
DEPAKOTE ER
2/8/2005
trandolapril
Tablets1 mg, 2 mg and 4 mg
MAVIK
10/4/2004
divalproex sodium
Extended-release Tablets250 mg
DEPAKOTE ER
5/3/2004

Non-Orange Book Patents for Abbvie

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,428,814 Bioadhesive nanoparticulate compositions having cationic surface stabilizers► Subscribe
6,818,229 Intermediate release nicotinic acid compositions for treating hyperlipidemia► Subscribe
9,452,194Methods for treating HCV► Subscribe
8,333,990Solid pharmaceutical dosage form► Subscribe
9,586,978Anti-viral compounds► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Abbvie Drugs

Country Document Number Estimated Expiration
Brazil0210561► Subscribe
Poland334477► Subscribe
Eurasian Patent Organization200401210► Subscribe
Hong Kong1117417► Subscribe
Portugal1315502► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Abbvie Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0030France► SubscribePRODUCT NAME: EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 32075 20060623; FIRST REGISTRATION: LI - 55783 01 20020607
/2000Austria► SubscribePRODUCT NAME: EPROSARTAN, AUCH IN FORM PHARMAZEUTISCH VERTRAEGLICHER SALZE WIE EPROSARTAN MESYLAT; NAT. REGISTRATION NO/DATE: 1-22115, 1-22114, 1-22117 19970930; FIRST REGISTRATION: DE 39573.00.00 - 39573.02.00 19970417
C/GB98/031United Kingdom► SubscribePRODUCT NAME: 2-BUTYL-4-CHLORO-1-((2'-(1H-TETRAZOL-5-YL) BIPHENYL-4-YL)-METHYL)-5-(HYDROXYMETHYL)IMIDAZOLE (LOSARTAN),OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR A POTASSIUM SALT( LOSARTAN POTASSIUM) AND HYDROCHLOROTHIAZIDE,; REGISTERED: FR 338520.7 19950215; FR 558453.7 19950215; UK 00025/0338 19960412
0150015 00143Estonia► SubscribePRODUCT NAME: DASABUVIIR;REG NO/DATE: EU/1/14/983 19.01.2015
C/GB08/020United Kingdom► SubscribeSUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB08/020 GRANTED TO ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. IN RESPECT OF THE PRODUCT RALTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, ESPECIALLY THE POTASSIUM SALT, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6346 DATED 05 JANUARY 2011 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 01 JANUARY 2023.
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Johnson and Johnson
Daiichi Sankyo
Chinese Patent Office
Federal Trade Commission
Accenture
Cerilliant
Deloitte
Healthtrust
Harvard Business School
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot